Information Provided By:
Fly News Breaks for February 24, 2020
BIIB, SNY, DNLI
Feb 24, 2020 | 07:04 EDT
As previously reported, Jefferies analyst Michael Yee initiated coverage of Denali Therapeutics (DNLI) with a Buy rating and $35 price target. Yee sees "lots of catalysts in 2020" that could move shares of Denali higher, including new Phase I/II data for DNL151 expected mid-year, Phase I/II data mid-20 from DNL747 with Sanofi (SNY), and BBB platform Phase I data for new IDS enzyme replacement by year-end. He also sees a potential "wave of Street enthusiasm in the neuro space" depending on what happens with the FDA and Biogen's (BIIB) aducanumab, telling investors that Denali will be a "clear beneficiary" if the FDA is amenable to a different bar in the huge unmet area of need in Alzheimer's.
News For DNLI;SNY;BIIB From the Last 2 Days
SNY
Mar 27, 2024 | 06:16 EDT
Wells Fargo analyst Derek Archila raised the firm's price target on Annexon (ANNX) to $12 from $11 and keeps an Overweight rating on the shares. The firm believes the risk/reward remains favorable ahead of ANX005's Phase 3 data in GBS. Additionally, updates for ANX007 at ARVO, Phase 3 GBS data at PNS and read through from Sanofi's (SNY's) riliprubart in CIDP at AAN, all could offer upside for shares, Wells adds.